Read about a major out-licensing partnership transferring a clinical-stage Alzheimer's therapeutic platform and its commercial and strategic implications.
Key Takeaways
- Out-licensing and collaboration deal is valued at more than $2.2 billion
- Global rights to the NeuroRestore platform including clinical-stage candidate ACD856 were granted
- AlzeCure will receive $12 million upfront including a $5 million investment and milestone-linked royalties